<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942042</url>
  </required_header>
  <id_info>
    <org_study_id>17154</org_study_id>
    <secondary_id>I1F-JE-RHCV</secondary_id>
    <nct_id>NCT03942042</nct_id>
  </id_info>
  <brief_title>A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis</brief_title>
  <official_title>A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug ixekizumab is safe and effective in
      participants with generalized pustular psoriasis and erythrodermic psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 5, 2019</start_date>
  <completion_date type="Anticipated">July 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 22, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants who Improved Global Improvement Score (GIS) at Least 1 Point from Week 12 and with ≤2 of GIS</measure>
    <time_frame>Week 12 through Week 20</time_frame>
    <description>Number of Participants who Improved Global Improvement Score (GIS) at Least 1 Point from Week 12 and with ≤2 of GIS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with GIS grade 1: Resolved</measure>
    <time_frame>Week 20</time_frame>
    <description>Number of Participants with GIS grade 1: Resolved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with GIS grade 2: Improved</measure>
    <time_frame>Week 20</time_frame>
    <description>Number of Participants with GIS grade 2: Improved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with GIS grade 3: Unchanged</measure>
    <time_frame>Week 20</time_frame>
    <description>Number of Participants with GIS grade 3: Unchanged</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with GIS grade 4: Worsened</measure>
    <time_frame>Week 20</time_frame>
    <description>Number of Participants with GIS grade 4: Worsened</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Achieved static Physician Global Assessment (sPGA) (0, 1)</measure>
    <time_frame>Week 20</time_frame>
    <description>Number of Participants who Achieved sPGA (0, 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Achieved at Least a 75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score (PASI 75)</measure>
    <time_frame>Week 20</time_frame>
    <description>Number of Participants who Achieved at Least a 75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score (PASI 75)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Psoriasis Scalp Severity Index (PSSI) in Participants with Scalp Involvement at Baseline</measure>
    <time_frame>Baseline, Week 20</time_frame>
    <description>Change from Baseline in PSSI in Participants with Scalp Involvement at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis</measure>
    <time_frame>Baseline, Week 20</time_frame>
    <description>Change from Baseline in Percent of BSA Involvement of Psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology Life Quality Index (DLQI) Total Score</measure>
    <time_frame>Baseline, Week 20</time_frame>
    <description>Change from Baseline in DLQI Total Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Developed Treatment-Emergent Anti-Ixekizumab Antibodies (TE-ADA)</measure>
    <time_frame>Week 20</time_frame>
    <description>Number of Participants who Developed TE-ADA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Developed Neutralizing Anti-Ixekizumab Antibody (NAb)</measure>
    <time_frame>Week 20</time_frame>
    <description>Number of Participants who Developed NAb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generalized Pustular Psoriasis (GPP) Only: Change from Baseline on Generalized Pustular Psoriasis Severity Index</measure>
    <time_frame>Baseline, Week 20</time_frame>
    <description>Change from Baseline on Generalized Pustular Psoriasis Severity Index</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Generalized Pustular Psoriasis</condition>
  <condition>Erythrodermic Psoriasis</condition>
  <arm_group>
    <arm_group_label>Ixekizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixekizumab given subcutaneously (SC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixekizumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Ixekizumab</arm_group_label>
    <other_name>LY2439821</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present with GPP or EP based on an investigator-confirmed diagnosis and meet the
             associated criteria

               -  GPP: Meet the criteria for GPP set by Ministry of Health, Labour and Welfare
                  (MHLW) at screening and baseline regardless of IL-36 mutation status.

               -  EP: Diagnosed to have BSA ≥80% involvement (with inflammatory erythema) at
                  screening and baseline.

          -  Candidates for phototherapy and/or systemic therapy

          -  Men must agree to use a reliable method of birth control during the study

          -  Women must agree to use birth control or remain abstinent during the study and for at
             least 12 weeks after stopping treatment

        Exclusion Criteria:

          -  History of drug-induced psoriasis

          -  Concurrent or recent use of any biologic agent

          -  Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks
             prior to enrollment and during the study

          -  Have previously received ixekizumab

          -  Serious disorder or illness other than psoriasis

          -  Serious infection within the last 12 weeks

          -  Breastfeeding or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospital</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173 8606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jikei University School of Medicine</name>
      <address>
        <city>Minato-Ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Medical School Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 15, 2020</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Generalized Pustular Psoriasis (GPP)</keyword>
  <keyword>Erythrodermic Psoriasis (EP)</keyword>
  <keyword>Japan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

